100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Block 2.1 Circulation and Lungs Summary $6.41
Add to cart

Summary

Block 2.1 Circulation and Lungs Summary

 262 views  1 purchase
  • Course
  • Institution
  • Book

This document includes all the cases, lecture notes and skills labs from block 2.1 (from 2016). It is extensive and includes all the details you need to go from a general overview to a precise picture. Written by someone who passed with a 'good'.

Preview 4 out of 106  pages

  • No
  • Circulation and lungs
  • October 8, 2017
  • 106
  • 2016/2017
  • Summary
avatar-seller
Fiche de Revision - Circulation and Respiration

Case 1: Atherosclerosis

I. Clinical Presentation of Atherosclerosis

1. Pathogenesis

- response to injury:
- injuries: endothelial dysfunction, hemodynamic disturbances, hypercholesterolemia, toxins,
inflammatory toxins
- LDL: impairs endothelial functions, increases ROS production, destroys NO
- location: areas of turbulent blood flow ; large/medium elastic and muscle arteries (coronary,
carotid, cerebral, aorta, major limb arteries)
-




development:

, - net effect of risk factors: inhibition of NO production ; stimulate production of adhesion
molecules, pro-inflammatory cytokines, chemotactic proteins, vasoconstriction
- steps:
- oxidized LDL
a) Fatty Streak
- endothelial binding of monocytes/T-cells
- migration of these to the subendothelial space
- initiation and perpetuation of local vascular inflammatory response
- lipids taken up/oxidised by the macrophages > results in foam cells

b) Atheroma
- macrophages produce cytokines which recruit smooth muscle cells ; increase ECM
- hypoxia in the plate causes cell death (worsening)
= subendothelial fibrous plaque w/ fibrous cap (intimal smooth muscle cells) surrounded by
connective tissue & intra/extracellular lipids + calcification w/i the plaque
- note: smooth muscle have receptors for LDL
- composition:
- lipid, lipid laden foam cells < inflammatory and smooth muscle cells < connective tissue
matrix (~ thrombi, Ca2+)
- types of atheromas:
- stable: collagen degradation/synthesis ratio in the smooth muscle cells (PDGF, FGF, TGDa)
- unstable: inflammatory cytokines, breakdown of ECM, high macrophage content, thick lipid
core, thin fibrous cap

2. Risk Factors

- 2 types:
- constitutional: genes, family, history, age, gender
- genetic: PCSK9 gene codes for LDL receptors for uptake from the blood
- gender: premenopausal women have a lower risk than men (estrogen protects)
- acquired: lifestyle choices, hyperlipidemia, hypertension, smoking, diabetes, obesity,
metabolic syndrome, etc…
- dyslipidemia: high total, high LDL/low HDL cholesterol

, - high LDL: oxidation, uptake causes increase of adhesion molecules, cytokines,
antigenic effect, T cell response, arterial wall inflammation
- normal HDL: reverse transport of LDL cholesterol; transport of antioxidant enzymes
- hypertension:
- vascular inflammation via angiotensin II mechanism
- angiotensin II stimulates endothelial cells/smooth muscle cells/macrophages to
produce atherogenic factors
- diabetes
- formation of AGEs ; increase of oxidative stress and ROS leading to endothelial injury
- smoking:
- nicotine/other chemicals toxic to the vascular endothelium
- increase in platelet reactivity (increase in thrombus formation risk)
- promotes vasoconstriction
- increases LDL, decreases HDL
- chronic inflammation: CRP production

3) Symptoms

- occur after the plaque has caused stenosis/acute plaque change = when blood flow is impeded
- typical signs:
- transient ischemia: angina pectoris, TIA (pre-stroke), intermittent claudication
- aneurysms, arterial dissection: pain, pulsatile mass, absent pulses, sudden death

4) Diagnosis

a) Symptomatic Patients
- basics: history/physical examination, fasting lipid profile, plasma glucose, glycosylated
hemoglobin levels
- systemic evaluation (despite localized symptoms)
- CT angiography w/ possibility of other imaging techniques

b) Asymptomatic Patients - Screening
- patients w/ risk factors but no symptoms
- blood tests: fasting lipid profiles
- urinary microalbuminuria (<30mg/24h)

II. Treatment and Management of Atherosclerosis

- goals: lower risk of clotting, widening/bypassing affected vessels, preventing complications
- basics:
- lifestyle: reduce obesity (BMI < 25), stop smoking, exercise, healthy diet

, - stabilize plaques
- antiplatelet, anticoagulants, antihypertensive medication
- diet: controlled BP and cholesterol, avoid diabetes 2
- no saturated fats, more omega 3, lots of soluble fibre
- surgery:
- angioplasty: procedure to open narrowed/blocked arteries ; can include stent placement
- bypass grafting: vessels from nearby body areas used to bypass the narrowed vessels
- endarterectomy: removal of plaque build up
- medications:
- commonly: anticoagulants, beta blockers, Ca channel inhibitors, niacin, statins,
thrombolytics, ACE inhibitors, diuretics, nitrates
- statins:
- lowers LDL cholesterol by reducing LDL production in the liver (1ry, 2ry prevention)
- mechanism: competitive inhibition of HMG-CoA reductase
- HMG-CoA reductase: first enzyme in cholesterol producing pathway mevalonate
- other effects: increase in LDL receptors to clear the LDL-cholesterol ; lowers blood
triglycerides
- nitrates (prodrug)
- vasodilator: donation of NO by reduction (w/ exception of certain forms where the nitrate is
in the correct state)
- mechanism: NO stimulates guanylate cyclase in vascular smooth muscle > GTP to cGMP >
protein kinase G activated > phosphorylation of proteins decreasing intracellular Ca2+ > muscle
relaxation > dilation
- acts primarily on veins = increases capacity of venous pool

III. Complications

- 2 major consequences:
- atherosclerotic stenosis: protrusion of the plaque into the lumen, leading to decrease of blood
flow
- acute plaque change: ruptured plaque causing thrombosis; erosion in the subendothelial
basement membrane; haemorrhage into the atheroma (can be caused by adrenergic
stimulation)
- physiology of acute plaque change:
- rupture: MTPs (metalloproteinases), cathepsins, collagenases, produced by plaque
macrophages
- these digest the fibrous cap causing thinning and rupture
- T cells secrete cytokines preventing smooth muscle recruitment
- 5 outcomes:
- thrombus organized/incorporated into a plaque leading to rapid plaque growth
- thrombus occludes vascular lumen, precipitates an ischemic events

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller anasanchez-moreno. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $6.41. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

53022 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$6.41  1x  sold
  • (0)
Add to cart
Added